Podcasts about Roche

Mercredi, le Trésor américain a racheté sa propre dette pour faire baisser ses taux. Le marché a effacé l'opération en une seule séance. Cette semaine, personne n'a réparé le mur. On a acheté du mastic. Scott Bessent regarde le 30 ans américain taper 5,34%, son plus haut depuis dix-neuf ans, décrète que ce n'est pas « justifié par les fondamentaux », et annonce qu'il double ses rachats de dette longue. Quatre milliards de dollars par opération. Le même jour, à la même heure, la dette américaine franchit les quarante mille milliards. Quatre milliards sur quarante mille milliards. Un franc sur dix mille. Devant témoins. En le disant très fort. Ça a tenu vingt-quatre heures. Et en face, Kevin Warsh ne dit rien. Il a supprimé la forward guidance, il explique tranquillement que la hausse des taux longs lui rend service, et il veut VENDRE exactement ce que le Trésor est en train d'ACHETER. Une main de l'État américain vend ce que l'autre main achète, le même jour, sur le même papier. Au menu également : le Brent à 94 dollars, la citerne à mazout de l'Europe remplie aux trois cinquièmes au pire moment de l'année Walmart qui se prend 9% dans les dents pour neuf dixièmes de point d'écart Geberit qui vend sa deuxième mi-temps au prix de la première, Roche et Holcim qui sortent un milliard et demi un jeudi soir sans que personne ne s'en aperçoive Nestlé dont on veut saisir les usines russes, et trois anomalies qui, mises bout à bout, ne sont pas très rassurantes. Et mercredi prochain, Nvidia passe son contrôle technique trimestriel. On en reparle. Il y a deux façons de raconter cette semaine. La confortable et l'autre. Les deux sont vraies. Dites-moi en commentaire laquelle vous choisissez — histoire numéro un ou histoire numéro deux. Le Swiss Bliss, c'est tous les samedis matin. Et on se retrouve dès lundi pour le Morningbull Live, du lundi au vendredi. On like, on commente, on partage, et on s'abonne. Merci d'être là aussi nombreux à chaque fois.

Ursprünglich war das Roche-Parkhaus eine temporäre Lösung. Nach dem Bau der Türme sollte es abgerissen werden. Nun will die Basler Regierung das Parkhaus aber stehenlassen und stösst damit die nächste Diskussion um Parkplätze in der Stadt an. Ausserdem: · Nach dem Streit zwischen EVP und Grünen um die Baselbieter Regierungsrats-Ersatzwahl: Wie steht es nun um die Stimmung zwischen den Fraktionspartnern? · 10 Jahre Basler Filmförderung: Wie hat sich die Branche entwickelt? · Endlich Regen nach wochenlanger Trockenheit: Welche Auswirkungen hat das auf die Abwasserreinigung?

La circulation des camions transportant du carburant exceptionnellement autorisée le week-end passé. Face à la pénurie des hydrocarbures dans la région, des mesures ont été appliquées par les autorités. Un trafic fluvial réduit à cause des fortes chaleurs et de la sécheresse explique ce phénomène. Un appel à idées pour tendre vers une économie durable. Le PETR Sélestat Alsace Centrale souhaite soutenir les initiatives locales en matière de circuits courts, de réemploi et d'économie circulaire. Pour cela, un accompagnement gratuit sera proposé aux quatre propositions sélectionnées. Cet appel correspond à un constat effectué sur le terrain. Tous les secteurs ou domaines d'activité sont concernés par cet appel à idées. Associations, communes, entreprises ou encore porteurs de projets individuels peuvent notamment y prendre part. Les candidatures sont ouvertes jusqu'au 30 septembre. Retrouvez notre article complet sur azur-fm.com. De nombreux travaux de voirie débutent cette semaine en Alsace. La route express de la Vallée de la Bruche est notamment coupée à la sortie de Saint-Blaise-la-Roche, en venant de Fouday. Jusqu'au 25 septembre, une zone d'apaisement de la vitesse sera créée, en approche d'un futur giratoire. Dans le Haut-Rhin, des travaux de réfection se tiendront jusqu'au 11 septembre entre Lapoutroie et Kaysersberg Vignoble, et sur la route du Rhin à l'Est de Rouffach jusqu'au 28 août. Dans toutes ces situations, des déviations ont été mises en place. Les conditions de circulation sont à retrouver sur inforoute.alsace.eu.Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Cette semaine, le marché a fait du tri sélectif. Il a gardé un dixième de pourcent d'inflation, et il a jeté la guerre au container. Wall Street a fini la semaine dans le vert. Le Russell 2000 a battu un record. Le VIX est tombé à son plus bas depuis le 31 décembre 2025 — une époque où il n'y avait ni guerre dans le Golfe, ni détroit d'Ormuz verrouillé. Pendant ce temps : deux navires attaqués dans le détroit, le consommateur américain qui rend les armes, la confiance des ménages qui s'écroule, et le trente ans américain qui tape 5,26%, son plus haut depuis juin 2007. Les deux histoires sont vraies. Le marché en a choisi une seule. Dans cet épisode : pourquoi les mauvaises nouvelles économiques sont devenues des raisons d'acheter, pourquoi l'obligataire refuse de participer à la fête, ce qu'Alcon nous apprend en cramant un demi-milliard de dollars sans que personne ne bronche, où en est vraiment le dossier des fonds propres d'UBS, et pourquoi votre deuxième pilier dépend aujourd'hui de l'humeur matinale du ministre pakistanais de la Défense. Bon week-end.

Moog CEO Pat Roche on expansion plans full 505 Fri, 14 Aug 2026 18:41:50 +0000 BzFGtgp2eJPGHqPxdR8L6K7olKIsywdS news WBEN Extras news Moog CEO Pat Roche on expansion plans Archive of various reports and news events 2024 © 2021 Audacy, Inc. News https://player.amperwavepodcasting.com?feed-link=https%3A

Send us Fan MailCan a treatment decision depend on whether one pathologist sees 45% biomarker positivity and another sees 55%?Visual immunohistochemistry scoring helped establish precision oncology. But as targeted therapies become more sensitive to subtle biological differences, categorical scores such as 0, 1+, 2+, and 3+ may no longer capture the information needed to identify the right patients.In this episode, I speak with three Roche experts:Gordana Juric-Sekhar, MD, anatomic pathologistSaleh Miri, PhD, Director of Digital Pathology AI AlgorithmsPurvi Gaglani, Regulatory Affairs Lead for Digital PathologyWe discuss how computational pathology is changing companion diagnostics by moving biomarker assessment from visual estimates to continuous, cell-level measurements.The conversation examines the limitations of manual IHC scoring, including interobserver variability, intraobserver variability, visual fatigue, borderline cases, tumor heterogeneity, and the inability of the human eye to measure complex spatial relationships.Using TROP2 scoring in advanced non-small cell lung cancer as an example, Saleh explains the normalized membrane ratio. This computational metric measures protein expression at the cell membrane relative to total expression within the cell—something that can't be reproduced through conventional visual scoring.We also clarify the difference between computer-assisted scoring and a fully computational companion diagnostic. An assisted tool supports a pathologist's visual interpretation. A computational CDx generates the biomarker measurement through algorithmic, cell-level analysis.That doesn't remove the pathologist.Pathologists remain responsible for evaluating tissue quality, staining quality, scan quality, tumor selection, image analysis results, and the final clinical context. They can reject a stain, request a rescan, exclude inappropriate regions, question the result, or seek a second opinion.The episode also examines the regulatory implications of computational companion diagnostics. Instead of evaluating a single IHC assay, regulators may need to assess the complete system - from tissue preparation and staining to scanning, image management, algorithmic analysis, display, and the final biomarker report.Finally, we discuss what laboratories will need to implement these workflows, including validated scanning infrastructure, cybersecurity, tighter preanalytical process control, and training that helps pathologists interpret continuous computational measurements.Episode Highlights00:00 — Pathologists remain central to computational CDxWhy computational tools provide more precise measurements without replacing pathology expertise.01:09 — Why companion diagnostics are changingVisual IHC scoring helped launch precision oncology, but the model is approaching its limits.04:53 — The current companion diagnostic landscapeHow IHC, next-generation sequencing, liquid biopsy, and visual biomarker scoring are used today.07:01 — The mathematical burden placed on the human eyeWhy manually assessing tens of thousands of tumor cells requires pathologists to estimate rather than calculate.08:39 — The borderline patient dilemmaA digital tool can distinguish measurements such as 74% and 76%, while that difference is difficult to reproduce visually.09:27 — Why spatial context mattersComputational pathology can measure biomarker heterogeneity, clustering, and relationships between tumor and immune cells.12:17 — Where manual scoring reaches its limitsInterobserver variability, intraobserver variability, fatigue, staining interpretation, and heterogeneous tumors.18:29 — Moving from judgment calls to quantified measurementsWhy the next stage of precision oncology requires information beyond human visual perception.19:14 — Computer-assisted scoring versus computational CDxThe important distinction between helping a pathologist calculate an existing score and generating a new algorithmic measurement.23:22 — Computational pathology and decentralized workflowsHow digital images can support remote review, access to expertise, and second opinions.27:48 — Why therapies require higher-resolution biomarkersModern targeted treatments may respond to biological differences that categorical scoring can't capture.32:09 — TROP2 in advanced non-small cell lung cancerThe episode's example of a biomarker requiring computational measurement.33:26 — Understanding the normalized membrane ratioHow the algorithm measures membrane expression relative to total protein expression at the individual-cell level.35:46 — Working with regulators on a new diagnostic modelPurvi discusses global health authority engagement and the FDA Breakthrough Device Designation.38:33 — The computational CDx as a system of systemsWhy staining, scanning, image management, algorithms, displays, and reporting must be evaluated together.40:11 — Changes to validated workflow componentsHow using a different scanner, monitor, or other component could fall outside the defined device configuration.43:30 — Why computational pathology is becoming necessaryContinuous measurements can reveal biomarker-treatment relationships that may remain hidden within categorical scores.49:12 — The pathologist's role in the workflowReviewing sample, staining, scan, image, algorithmic analysis, and the final biomarker result.53:39 — Digital second opinionsHow image management systems can simplify collaboration without physically transporting glass slides.56:43 — What laboratories need to prepareValidated infrastructure, cybersecurity, preanalytical control, training, and digital pathology literacy.58:49 — Learning to interpret computational resultsThe shift from visually estimated categories to continuous, quantitative biomarker measurements.Resources MentionedFull discussion on YouTube: https://youtu.be/oKW1xC6TTZgListen to the full discussion to understand how computational pathology could change companion diagnostics—and what pathologists, laboratories, and regulators must prepare for next.Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Bristol Myers Squibb has selected Houston as the site for a new $2.3 billion multi-modal manufacturing campus designed to support drug product and finished goods manufacturing from late development through launch. Recursion, Roche, and its Genentech subsidiary have announced plans to co-develop a neuroscience discovery program based on the first validated target discovered through an AI map. Editors reminisce over the changes in science since the COVID-19 pandemic in light of a new large NIH-funded study that shows COVID-19 can reactivate dormant viruses, including Epstein-Barr and cytomegalovirus. In other infectious disease news, drug-resistant Candida auris was found to persist in hair follicles by exposing chitin, triggering interferon-γ that suppresses skin defenses and creates a niche for fungal colonization.Join GEN editors Corinna Singleman, PhD, Alex Philippidis, and Julianna LeMieux, PhD, for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base: BMS Chooses Houston for $2.3B Manufacturing FacilityBy Alex Philippidis, GEN Edge, Aug 10, 2026Next 10 U.S. Biopharma ClustersBy Alex Philippidis, GEN, Aug 12, 2026Recursion Partners with Genentech to Advance First Validated Neuro Target Discovered Through AI MapBy Alex Philippidis, GEN Edge, Aug 5, 2026COVID-19 Reactivates Dormant Viruses, Offering New Clues to Long COVIDGEN, Aug 5, 2026Trump's Treatments: Regeneron's Antibodies and Gilead's Remdesivir ExplainedBy Alex Philippidis, GEN, Oct 5, 2020Lessons from the COVID Crisis: An Interview with Peter HotezBy Alex Philippidis, GEN Edge, Oct 19, 2022How to Conquer Coronavirus: Top 35 Treatments in DevelopmentBy Alex Philippidis, GEN, March 2, 2020Candida auris Persists in Hair Follicles, Hijacks Immune SignalingGEN, August 10, 2026The State of Biotech SummitSeptember 23, 2026 Touching Base Podcast Hosted by Corinna Singleman, PhD Behind the Breakthroughs Hosted by Jonathan D. Grinstein, PhD The State of Biologics Testing 2026Charles River Laboratories and GEN, June 10, 2026Subscribe to GEN's newsletters Hosted on Acast. See acast.com/privacy for more information.

"Auch wenn man gar nicht so viel aktiv an der Börse ist, kann man trotzdem gute Renditen erwirtschaften. Aktiv bedeutet nicht: Ständig hin und her." Sebastian Steyers wikifolio "Qualitätsaktien aktiv" ( https://go.brn-ag.de/242 ) funktioniert über Diversifikation und Korrelation. So ist zum Beispiel Nvidia deutlich höher gewichtet als Rheinmetall. 46 Aktien stecken derzeit im Depot, darunter Cash Cows wie Amazon, Alphabet oder Apple. "Seit Jahresbeginn sind wir bei 11,7 % Rendite. Unter den großen Gewinnern: Applied Materials, Roche, Taiwan Semiconductor, Equinor, United Utilities." Unter den Kauf- und Aufstockungskandidaten befinden sich Hitachi, Aurubis, Siemens und NXP Semiconductors. "Mich reizt das Thema Robotik. Aurubis ist ein deutscher Top Player in der Kupferindustrie. Bei Siemens mache ich mir überhaupt keine Sorgen. NXP ist ein Philips-Spin-Off sowie eine Top-Aktie mit relativ moderater Bewertung." LS9MXG wikifolio Qualitätsaktien aktiv DE000LS9MXG9

HEADLINES: Thousands of students across the country are set to walk out of school and university today to protest the rise of Pauline Hanson and her political party, One Nation. Authorities are doing their best to quell serious concerns over the use of defibrillators in ambulances after a regulator paused sales of the device due to thousands of malfunctions in recent years. Federal police have raided over 100 service stations in a massive crackdown on illicit tobacco. The jury in Luigi Mangione's upcoming murder trial will be kept anonymous, a New York judge has ruled. Nicole Kidman has sent her old primary school a happy birthday message. Roger Federer's fortune has dropped below the billion-dollar mark. And it turns out your dog really can tell if you're happy or sad. GET IN TOUCHGot a story, news tip-off, feedback or dilemma?Send us a voice note or email us at thequicky@mamamia.com.au CREDITSHost: Charlotte Mortlock Audio Producer: Scott Stronach Group Executive Producer: Georgie Page Check out The Quicky Instagram here and our TikTok here Discover more Mamamia podcasts here Did you know some of our shows are now in video on the Apple Podcast app? Make sure your phone is up to date and check it out here! Mamamia acknowledges the traditional owners of the land on which we have recorded this podcast.Become a Mamamia subscriber: https://www.mamamia.com.au/subscribeSee omnystudio.com/listener for privacy information.

Technology is opening new possibilities for how multiple sclerosis is monitored, treated and managed. In this episode of the ECTRIMS Podcast, host Brett Drummond speaks with Prof. Ellen Mowry of Johns Hopkins University and Prof. Letizia Leocani of Vita-Salute San Raffaele University about how innovative medical technologies could transform MS research and clinical care. Together, they explore: How artifical intelligence, wearable devices and digital biomarkers could help monitor MS progression The potential to capture fatigue, cognition, pain, mood, sleep and other symptoms between clinical visits How passive monitoring could provide a more complete picture of everyday life with MS The growing role of virtual rehabilitation, digital therapies and other technologies in bringing care into people's homes Why digital biomarkers require rigorous research and validation before being used in clinical trials From earlier detection of disability progression to more accessible rehabilitation and personalised symptom management, this episode examines both the opportunities and challenges of using technology to improve MS care. --- This podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases, Bristol Myers Squibb, Novartis, Roche, Sanofi, and UCB. Educational grant providers have no input into the podcast series content.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the intricate web of scientific advancements, regulatory updates, and strategic maneuvers shaping the industry. Let's begin with Eli Lilly's impressive financial performance, clocking a record-breaking $23 billion in revenue for Q2 2023. This achievement, driven by the success of Mounjaro and Zepbound in metabolic diseases, underscores the competitive landscape of therapies targeting chronic conditions. However, the slower launch of Foundayo highlights ongoing challenges. Meanwhile, competition in obesity treatments is intensifying as Novo Nordisk's Wegovy continues to dominate despite new entrants like Eli Lilly's Foundayo. This scenario reflects growing patient preference for oral medications over injectables. Gilead Sciences' HIV prevention franchise has exceeded $1 billion in quarterly sales, reflecting an increasing reliance on effective small molecule therapies for infectious diseases. Gilead also remains a focal point with its HIV pre-exposure prophylaxis franchise reaching sales milestones amid legal victories defending their tenofovir-based treatments. These legal precedents could influence future innovation policies across the industry. Artificial intelligence continues to make waves in drug discovery and clinical trials. Icon's partnership with Anthropic aims to integrate AI capabilities to accelerate drug development timelines. Similarly, Phylo and Chugai Pharmaceutical are collaborating to optimize drug discovery workflows using advanced AI platforms. These collaborations highlight a strategic move towards enhancing efficiency in drug development processes. In oncology, Amplia Therapeutics and Eli Lilly are evaluating a combination therapy for non-small cell lung cancer, while Evexta Bio and Roche are exploring a joint study for metastatic breast cancer. These partnerships underscore the industry's focus on combination therapies and precision medicine to improve cancer treatment outcomes. Additionally, AstraZeneca's partnership with CSPC Pharmaceutical to enhance biologics manufacturing in China signifies the importance of localized production capabilities. On the regulatory front, Arrowhead Pharmaceuticals' acquisition of an FDA rare pediatric disease priority review voucher for Plozasiran represents a commitment to addressing unmet needs in rare diseases. This voucher could expedite new drug applications, potentially bringing life-saving treatments to patients more quickly. Despite these advancements, challenges persist. Novo Nordisk's Cagrisema failed to achieve its primary endpoint in a Phase 3 trial for type 2 diabetes, highlighting the complexities of developing combination therapies for metabolic disorders. Similarly, Eli Lilly's discontinuation of its Phase 1/2 trial for GBA1 gene therapy reflects the hurdles faced in advancing gene therapies. Looking at industry dynamics, Amgen's decision to discontinue its early-stage obesity drug signifies a strategic shift towards focusing on more promising pipeline candidates like Maritide. This move aligns with broader trends prioritizing candidates with significant potential impact on patient care. Amgen's 'Repatha' is experiencing renewed interest due to positive cardiovascular risk reduction data, showcasing how robust clinical results can rejuvenate existing products. In regulatory news, Merck's 'Lipfendra' has been spotlighted by the FDA as part of its Complex New Product Validation pilot program. This positions Lipfendra as a potential game-changer in the PCSK9 inhibitor category. Lastly, financial maneuvers such as Attovia Therapeutics' $289 million IPO and Expedition Therapeutics' $115 million Series B funding highlight investor confidence in novel therapeutic areas like dermatological and respiratory treatments. The pharmaceutical landscape remains dynamic with Johnson & Johnson investing heavily in gene therapy ventures like Sail Biomedicines for CAR-T therapies. Meanwhile, regulatory challenges persist as seen with Capricor's cell therapy setback due to statistical complexities during FDA reviews. Despite setbacks faced by some companies, innovations continue to thrive. The launch of personalized genetic therapy centers signals a shift towards individualized medicine while research into safer CAR-T therapies progresses. In conclusion, these developments reflect an industry driven by innovation amidst regulatory challenges and strategic adjustments. As companies navigate this evolving landscape, their decisions will shape future healthcare innovations and patient care outcomes. Thank you for joining us on Pharma Daily; stay tuned for more insights from the world of pharmaceuticals and biotech.Support the show

“The least expensive CDMO on the first day of bidding may not be the optimum value CDMO three years later.”Choosing a contract development and manufacturing organization is not about who quotes the lowest unit price. It's mainly about who keeps your clinical timeline intact.Prakash Savarirayan is a life sciences procurement leader with more than two decades of sourcing experience, over a dozen years of it in biopharma, including senior roles at Takeda (formerly Shire) and Roche's Spark Therapeutics. He has led complex CDMO partnerships, supported M&A integrations, and built governance models across small molecules, biologics, and gene therapy, and now advises pharma and biotech clients in consulting capacity.In the latest PharmaSource podcast episode, Prakash explains why getting CDMO selection right matters more than negotiating the lowest price, how procurement earned a strategic seat at the table, and why the right partner protects both patient safety and enterprise value.Read the full article.

Or did he? The 'zip it' crowd, known by some as Trad, Inc, makes the case that its Roche trying to force his stance on Leo. The idea that a soon to be retiring prefect is trying to force the Roman Pontiff to adopt his position might be the biggest case of cope I've seen yet.Sponsored by Nelson Insurance Advisorshttps://www.nelsonplan.comSources:https://substack.com/@returntotradition1Contact Me:Email: return2catholictradition@gmail.comSupport My Work:Patreonhttps://www.patreon.com/AnthonyStineSubscribeStarhttps://www.subscribestar.net/return-to-traditionBuy Me A Coffeehttps://www.buymeacoffee.com/AnthonyStinePhysical Mail:Anthony StinePO Box 3048Shawnee, OK74802Follow me on the following social media:https://www.facebook.com/ReturnToCatholicTradition/https://twitter.com/pontificatormax+JMJ+#popeleoXIV #catholicism #catholicchurch #catholicprophecy#infiltration

Chronic liver disease affects around 1.5 billion people globally. As understanding of liver disease improves, outcomes are increasingly determined by how early patients are identified, not just what therapies are available. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Lee Lehman Becker, Roche's global head of healthcare insights at Roche Information Solutions (RIS), for a discussion of the liver disease epidemic that is being diagnosed too late and driving a growing health system crisis globally. The conversation also explores scalable diagnostic innovation and the role of this in addressing health system burden – metabolic liver disease projected to affect some 1.8 billion people by 2050, with global costs expected to exceed $2.3 trillion. You can listen to episode 271 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

The Public Service Commissioner's defending a probe into controversial ads, that cost much more than the ads did. In October, the Commission paid 426 dollars and 32 cents to to boost ads on social media, opposing mass strike action. An external probe, costing roughly 60-thousand dollars, found the Commission didn't breach neutrality standards, but risked the perception of that. Sir Brian Roche told Ryan Bridge the report provided clarity. He says he felt compelled to correct the narrative from some unions - and says he'd do this again if needed, but with more thought. LISTEN ABOVESee omnystudio.com/listener for privacy information.

Today's Sponsors: https://iCatholicMobile.com Visit iCatholicMobile.com and switch to a faithful Catholic phone coverage or call 802-988-6588 Real Estate for Life: https://realestateforlife.org/ (and select "Dr. Taylor Marshall Show") https://nsti.com/checkout/?rid=pJNK69 This is the NSTI discount link to receive your $1 jump start at New Saint Thomas Institute for your Catholic Bible in a Year, Catholic Bible Cheat Sheet, and Catholic Lifetime Reading List and 10 Catholic Courses from Dr. Taylor Marshall. Learn more about your ad choices. Visit megaphone.fm/adchoices

July 30th, 2026 - We welcome back Nick Cavazos to offer thoughts on Dr. Anthony Fauci pleading the fifth. Then, we welcome back Michael Matt to discuss Cardinal Roche's declaration that Pope Leo is NOT changing restrictions on the Traditional Latin Mass. Links, Show Notes & More - https://thestationofthecross.com/act Email Us! ACT@TheStationOfTheCross.com

Building real community as an adult is quietly one of the hardest things about modern life, and it gets harder when you're Childfree. The friends you assumed would always be around get busy, have kids, or move away, and one day you look up and realize the built-in social life adulthood promised never actually arrived. Maddy Roche sits down with four people who got tired of waiting and built the communities they couldn't find. Kari Cardinale of the Modern Elder Academy, Florence Wlodarski of Parallel Social Club, and Charlie and Ali Higgins of DINK Social each started from the same quiet ache, wanting people whose weekends were free and whose lives looked like theirs, and turned it into something thousands have now joined. Underneath it all sits a striking finding: the single biggest predictor of a long life is not diet or exercise, but the quality of the friendships you build in midlife.In This Episode, You'll Learn:Why finding your people gets harder in your 40s and beyond, the specific friction points that make adult friendship so difficult, and how these community builders designed around every one of themHow three very different organizations approach the same need, from a midlife wisdom school to an in-person social club to an app built specifically for Childfree couplesWhy the first hangout is only the entry point, and how structured, smaller gatherings create the deeper "third vault" conversations that actually bond people togetherWhat it takes for an introvert to walk into a new community and get the most out of it, including why small, vetted, interest-based groups beat big networking-style eventsThe 80-year Harvard finding that the quality of your midlife friendships predicts a long life more than diet or exercise, and why that reframes community as a health priorityEpisode Guests:Kari Cardinale is a partner and Chief Content Officer at MEA (Modern Elder Academy), a midlife wisdom school with campuses in Baja, Mexico, and Santa Fe, New Mexico, plus a digital campus and an alumni community of 8,000 people across 60 countries, all built around navigating midlife and building new friendships.MEA (Modern Elder Academy): meawisdom.comFlorence Wlodarski is the co-founder of Parallel Social Club, a social wellness community in Los Angeles built for DINKs, SINKs, Childfree, and childless adults. Parallel hosts around ten small, curated in-person events a month, designed to remove the friction from adult friendship and help busy professionals actually connect.Parallel Social Club: parallelsocialclub.com Charlie and Ali Higgins are the co-founders of DINK Social, a social app built exclusively for Childfree couples to connect, discover events, and build real friendships. Launched in early 2026, the community-driven platform has already surpassed 2,500 couples.DINK Social: dinksocial.com Episode Host:Maddy Roche is the Chief Growth Officer at Childfree Trust®, where she leads all sales, marketing, and partnership initiatives and brings sharp insight to estate planning, LGBTQ+ legacy considerations, and Childfree financial decision making.About Childfree Insights:Childfree Insights delivers education for financial and estate planning without children. It supports people with no kids in making informed decisions about retirement, legacy planning, beneficiaries, and long-term care. Home of Childfree Wealth® and Childfree Trust®.Connect with Us:Ready to work on building better financial habits? Connect with our financial planning team at childfreewealth.com or learn more about estate planning at childfreetrust.com.Follow Childfree Life by Design on your favorite podcast platform and join the conversation on social media:Instagram: https://www.instagram.com/childfreeinsightsFacebook: https://www.facebook.com/ChildfreeInsights/LinkedIn: https://www.linkedin.com/company/childfreeinsightsYouTube: https://www.youtube.com/@ChildfreeInsightsDisclaimer: This podcast is for educational & entertainment purposes. Please consult your advisor before implementing any ideas heard on this podcast.

Fresh out of the studio, Sophie Dionnet, Senior Vice President of Product and Business Solutions at Dataiku, joins us at the Dataiku Summit in Singapore to discuss what turns enterprise AI investment into measurable value. She lays out the three ingredients Dataiku builds around — the right people, orchestration across technologies, and supporting controls — and makes the case that governance is a scaling mechanism rather than a brake. She points to Roche, where a patent lawyer encoded his own professional expertise into a working system of agents, discusses Dataiku's answer to agent sprawl with agent management launching in October, and closes on strong momentum across banking and the public sector in Asia Pacific."A lot of the changes that organizations need to do today actually don't require the latest model. That's not really the problem. It's about doing the hard thing, the change, the things that we talked about. It's easier to be excited by the new toy than by trying to use it. And so yes, I think this is why there is a bit of a gold rush of trying to figure out where is it going to end. We don't know." - Sophie DionnetProfile: Sophie Dionnet, Senior Vice President of Product and Business Solutions at DataikuLinkedIn: https://www.linkedin.com/in/sophie-dionnet-a176894/Episode Highlights [00:00] Quote of the Day by Sophie Dionnet from Dataiku[01:00] Three angles: domain knowledge, orchestration, governance[01:59] What has not changed: data still decides everything[02:31] Data consciousness accelerated over the past twelve months[03:05] The LLM explosion and the raw-power question[03:51] Why Sophie pushed governance before the market asked[05:30] What Dataiku is, and where the name comes from[06:15] Three ingredients: people, orchestration, controls[07:22] Roche: a patent lawyer builds his own agents[08:51] Change management, not technology, is the gap[09:41] Decision takes an hour, implementation takes two years[09:58] Why domain knowledge beats model performance[11:30] Most changes do not require the latest models[11:58] The scaling belief the industry gets wrong[12:50] Centralisation risk and the rise of shadow AI[14:02] Where leaders still quietly choose to do nothing[15:22] Vibe coding, conflicting outputs, and lost consensus[16:43] The GDPR lesson on ex-post compliance cost[18:42] Why the agent question starts at the board[19:38] Agents are simply a new kind of API[20:28] Is agent sprawl technology or organisational design[21:28] What separates AI scalers from pilot purgatory[22:58] The bear case: foundation labs absorb the middle[23:45] Why every leading technology becomes self-centred[24:57] Vibe coding your own Salesforce, and why not[25:23] The pet store analogy for build versus buy[26:22] Systems of record and the real switching cost[28:30] Dataiku in Asia Pacific over the next three years[29:59] ClosingPodcast Information: Bernard Leong hosts and produces the show. The proper credits for the intro and end music are "Energetic Sports Drive." G. Thomas Craig mixed and edited the episode in both video and audio format.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a wealth of significant advancements and strategic moves shaping the industry landscape. AstraZeneca is making waves with its steadfast commitment to reaching an $80 billion revenue target by 2030. This ambitious goal is underpinned by strong sales in oncology and rare disease treatments, despite some setbacks with underperforming drugs like Ultomiris. The company's confidence is further reflected in its robust internal pipeline of antibody-drug conjugates (ADCs), even after discontinuing two candidates that fell short in clinical trials. This move highlights an industry-wide focus on high-potential therapeutic areas, underscoring the critical role of sustained innovation in preserving market leadership. In leadership news, Sarepta Therapeutics has appointed Michael Severino as CEO, succeeding Doug Ingram. Severino's extensive experience from AbbVie and Tessera signals a strategic shift for Sarepta, especially as it hones its focus on therapies for Duchenne Muscular Dystrophy. Leadership transitions like this can significantly impact a company's strategic direction, potentially steering it toward new therapeutic breakthroughs. On the regulatory front, Otsuka's Simtriyo has received FDA approval, marking it as a first-in-class norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) for ADHD. This approval is a major leap forward in central nervous system therapeutics, offering a non-stimulant option that could become a blockbuster drug in this underserved market. Such advancements highlight the persistent need for innovative treatments in CNS disorders. Similarly, Outlook Therapeutics has achieved FDA approval for Lytenava, a reformulated version of Roche's Avastin for wet age-related macular degeneration (AMD). This victory, following three prior rejections, exemplifies the challenges and opportunities inherent in drug reformulation and regulatory perseverance. Corporate acquisitions continue to shape industry dynamics. Argenx's acquisition of Forte Biosciences for $2.2 billion exemplifies strategic investments aimed at expanding therapeutic portfolios. Forte's promising Phase 2-stage vitiligo drug acquisition underscores the industry's shift towards biologics in managing complex autoimmune disorders. Amgen's recent layoff of approximately 40 employees aligns with broader trends of operational optimization amidst organizational restructuring. Such workforce adjustments often reflect shifts in business strategy or responses to evolving market conditions. In clinical development news, InnoCare Pharma has announced successful Phase 3 results for its oral TYK2 inhibitor Fadeucravacitinib in treating moderate-to-severe plaque psoriasis. This achievement underscores the potential of targeted therapies in addressing autoimmune conditions by modulating specific signaling pathways. The FDA's approval of Freenome's SimpleScreen CRC blood test marks a significant advancement in non-invasive diagnostic tools for colorectal cancer screening. Such innovations could dramatically impact early cancer detection and improve patient outcomes. Meanwhile, emerging insights into CAR-T therapy have identified genetic markers linked to toxicity risks in Yescarta patients. These findings can guide future CAR-T product development towards enhanced safety profiles, offering pathways for engineering safer therapies by identifying patients at higher risk for adverse effects. Finally, the partnership between Salesforce and Veterans Affairs aims to integrate AI into healthcare workflows, illustrating the increasing role of digital transformation in enhancing healthcare delivery and operational efficiency. These developments highlight the ongoing evolution towards more personalized and efficient healthcare solutions within the pharmaceutical and biotech sectors. As companies navigate complex regulatory landscapes, pursue innovative therapies, and adapt to dynamic market demands, their efforts are poised to advance patient care standards and drive future growth within these critical industries. The implications for patient care are profound, as new treatments offer hope for conditions that have long eluded effective intervention. Stay tuned with Pharma Daily as we continue to bring you the latest updates from this rapidly evolving field.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into the latest groundbreaking advancements, strategic corporate maneuvers, and pivotal regulatory updates shaping this dynamic industry landscape. Starting with some exciting news, Scribe Therapeutics has successfully closed its initial public offering, raising a significant $129 million. This substantial funding will drive forward their pioneering work in gene editing technologies, particularly focusing on therapies for cardiovascular diseases and atherosclerotic cardiovascular disease (ASCVD). By leveraging CRISPR technology, Scribe Therapeutics is positioned at the forefront of developing transformative treatments for both rare and common diseases. This advancement could potentially revolutionize how these conditions are managed, offering new hope for patients worldwide. On the regulatory front, Amgen is actively working to maintain its competitive edge in the U.S. market by submitting a comprehensive data package to the FDA for its drug Tavneos. This strategic move highlights the competitive nature of the pharmaceutical landscape where maintaining market access and drug positioning is crucial. Additionally, an FDA panel has recently endorsed lifting restrictions on four peptides, a decision that could significantly enhance therapeutic options in wound healing and autoimmune diseases through compounding pharmacies. This shift indicates a broader acceptance of peptides' therapeutic potential, which are increasingly being explored for their targeted therapy applications. In clinical trial news, Meiji Seika Pharma has reached a significant milestone with its combination therapy involving HBI-8000 and nivolumab. The therapy has successfully met the progression-free survival endpoint in a Phase 3 trial for advanced melanoma. This approach combines an epigenetic immunomodulator with a PD-1 inhibitor, representing a strategic method to harness immune system modulation for cancer treatment. Such advancements highlight ongoing innovations within oncology therapeutics and emphasize opportunities for improved patient outcomes through novel treatment combinations. However, not all clinical trials meet success. Sanofi's recent decision to halt Phase 3 development of amlitelimab for atopic dermatitis due to insufficient data serves as a reminder of the inherent challenges in drug development. Similarly, Ipsen's Bylvay did not meet its primary endpoint in a pivotal trial for biliary atresia patients post-Kasai surgery. These setbacks highlight the complexities involved in translating scientific discoveries into viable therapeutic options and underscore the unpredictable nature of drug development. Shifting to corporate strategies, Roche has decided to discontinue its development of an obesity asset, acmopatide, while placing support behind another candidate, enicepatide. This decision reflects dynamic prioritization within pipelines as companies navigate scientific data alongside market demands. Meanwhile, Fresenius has launched a €200 million corporate venture capital fund targeting innovations across biopharma, medtech, and digital care sectors. This move aligns with an increasing trend towards supporting early-stage innovations addressing unmet medical needs. In mergers and acquisitions news, Scancell's acquisition of Neophoria Therapeutics via reverse merger showcases strategic maneuvers within the sector aimed at securing financial stability and market presence through listings such as on NASDAQ. These activities illustrate broader industry trends where companies seek growth through strategic partnerships and acquisitions to enhance technological capabilities and market reach. In oncology developments, GSK has achieved a landmark FDA approval for Jideytro following its acquisition of Nuvalent. This milestone underscores the strategic importance of mergers and acquisitions in achieving rapid growth and diversification in oncology pipelines. The quick payoff from this deal highlights how targeted acquisitions can accelerate therapeutic advancements. Turning our attention to HIV prevention strategies, Merck is expanding access to its investigational PrEP pill Alimatravir through voluntary licensing agreements even before regulatory approval. This proactive strategy mirrors Gilead's successful model and emphasizes the industry's shift towards accessibility and patient-centric approaches. Finally, technological advancements continue reshaping industry practices with AI integration into incentive compensation models being explored by companies like Novartis in collaboration with consulting firms such as ZS Associates. These efforts are part of a larger digital transformation within the industry aimed at enhancing operational efficiency and decision-making processes. As we wrap up today's insights, it's clear that these developments highlight an era where scientific innovation intersects with strategic business decisions and regulatory frameworks. The implications for patient care are profound as these efforts translate into more effective therapies with potential impacts on treatment accessibility, efficacy, and personalization. As the industry continues to evolve rapidly amidst scientific breakthroughs and regulatory changes, maintaining a balance between innovation, regulation, and market dynamics will be crucial for sustaining growth and improving health outcomes globally.Support the show

¿Has escuchado maravillas sobre medicamentos como Ozempic, Wegovy o Mounjaro, pero nadie te habla de las constantes náuseas y el malestar estomacal? La realidad clínica es que una gran parte de los pacientes abandonan estos tratamientos para la obesidad simplemente porque los efectos secundarios arruinan su calidad de vida. Pero la ciencia médica está a punto de dar un salto monumental. En este episodio, descubriremos a la AMILINA, una hormona producida por tu páncreas que está demostrando resultados asombrosos en ensayos clínicos: pérdida de peso significativa sin los severos vómitos ni malestares intestinales de los fármacos actuales. En este episodio aprenderás: → Cómo tu páncreas libera dos hormonas cada vez que comes. → Cómo la amilina bloquea el freno metabólico que hace que recuperes el peso perdido. → Cómo dos equipos de investigadores resolvieron el mismo problema químico de formas distintas. → Cómo la combinación CagriSema alcanza una reducción significativa del peso corporal. → Por qué la amilina resensibiliza tu cerebro a la leptina, algo que la semaglutida no logra.   Mi nombre es Dr. Mauricio González, médico internista y especialista en endocrinología en formación. Aquí comparto información basada en evidencia para que tomes decisiones de salud sin mitos ni marketing engañoso. Suscríbete a mi boletín informativo en: www.drmauriciogonzalez.com/   ⚠️ Este podcast tiene fines exclusivamente educativos e informativos y no constituye asesoramiento médico, diagnóstico ni tratamiento personalizado. Los medicamentos que se discuten en este episodio se encuentran en fase de investigación y no cuentan con aprobación de la FDA. Consulta siempre a tu médico o a un profesional de la salud calificado antes de cambiar tu régimen de tratamiento.   ¡Sigamos la conversación en redes sociales! Instagram

Loneliness carries the same health toll as smoking 15 cigarettes a day, and for Childfree adults there is no built-in carpool lane to friendship. You build your crew on purpose. In this episode, Melissa Holcombe, DSW, LCSW, Maddy Roche, Bri Conn, CFP®, and Alli Gage trade honest stories about the moments that forced them to rebuild their circles, from divorce and sobriety to cross-country moves, and the practical ways they found their people again. They get into why intergenerational friendships are a quiet superpower when your life is not organized around school pickups and playgroups, how to take the pressure off by letting not every friend be a best friend, and the small, repeatable habits, showing up a second time, raising your hand to volunteer, casting a wide net, that turn strangers into a community that fits the life you designed.In This Episode, You'll Learn:Why friendship is a health requirement rather than a nice-to-have, and what the research on loneliness, the friendship recession, and the emotional-support deficit reveals about how common it is to feel disconnectedHow major life changes like divorce, sobriety, and moving can signal that your crew needs to change, and how to rebuild intentionally by getting clear on how you want to spend your time and who you want around youWhy intergenerational friendships are a particular advantage for Childfree adults, and how connecting across age groups brings perspective, mentorship, and a richer lifeHow to take the pressure off friendship by connecting over one shared thing, since not every friend has to be a best friend for the relationship to be deeply satisfyingThe practical, repeatable moves for finding your people, from hobbies, classes, volunteering, and faith communities to apps like Bumble BFF and Meetup, plus why going back a second time changes everythingEpisode Hosts:Melissa Holcombe, DSW, LCSW is a Senior Advisor at Childfree Trust® with three decades in social services across child welfare, public schools, and guardianship and probate. She is also one of the nation's first Certified Veterinary Social Workers, with deep expertise in the legal and emotional terrain that vulnerable individuals navigate.Maddy Roche is the Chief Growth Officer at Childfree Trust®, where she leads all sales, marketing, and partnership initiatives and brings sharp insight to estate planning, LGBTQ+ legacy considerations, and Childfree financial decision making.Bri Conn, CFP® is a Childfree Wealth Specialist at Childfree Wealth® and Customer Experience Manager at Childfree Trust®. She specializes in financial management, life design, and estate planning, with particular focus on LGBTQ+ individuals and couples, drawing on her own early financial challenges and recovery to fuel her work in personal finance education.Alli Gage is the Chief of Staff at Childfree Insights, the behind-the-scenes coordinator who keeps all the organizations running in an orderly fashion across the board.About Childfree Insights:Childfree Insights focuses on planning for solo aging and later life without children. It offers trusted education on financial planning, estate planning, and building support systems for people aging independently. Home of Childfree Wealth® and Childfree Trust®.Connect with Us:Ready to work on building better financial habits? Connect with our financial planning team at childfreewealth.com or learn more about estate planning at childfreetrust.com.Follow Childfree Life by Design on your favorite podcast platform and join the conversation on social media:Instagram: https://www.instagram.com/childfreeinsightsFacebook: https://www.facebook.com/ChildfreeInsights/LinkedIn: https://www.linkedin.com/company/childfreeinsightsYouTube: https://www.youtube.com/@ChildfreeInsightsDisclaimer: This podcast is for educational & entertainment purposes. Please consult your advisor before implementing any ideas heard on this podcast.

Alphabet shares pare back overnight as investors scrutinise its ever-increasing capex plans. Tesla is also down after missing on earnings while free cash flow turns negative. Elsewhere, Unicredit raises its outlook after posting a beat on both the top and bottom lines as CEO Andrea Orcel tells CNBC the bank is firing on all cylinders. And forex headwinds take a bite out of Roche's first half sales, but the Swiss drugmaker confirms its full-year targets.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Second quarter earnings continue to roll with Novartis and Roche reporting this week; Eli Lilly's AtaiBeckley buy for up to $3.8 billion offers clear “validation” for the fledgling psychedelics space; more drama unfolds at FDA as the agency goes back and forth on its policy of publishing complete response letters in real-time; and IPO fever continues.  

Let us know your thoughts"Steg sat down with Demo_N Director Gary Francis Roche & Echo Cell Founder David Wing to discuss their careers and plans for the future. They also chatted about Vertical Films - Is vertical the future of horror? Find out here"Support the showIG - @thehorrorcutshow | @HewittGPro | @StephenkerrActor_PerformerFB - Facebook.com/profile.php?id=61573701383591

This episode was recorded in France at the 2026 Cannes Lions International Festival of Creativity and features a panel called “How Retail Media Becomes a Growth Engine” which was produced by EMarketer and sponsored by Sensor Tower, featuring Albertsons Media Collectives' Liz Roche, Omnicom's Claudia Johnson,  EMarketer's Sarah Marzano, Goodway Group's Angela Myers & Bain & Co's Shweta Bhardwaj.Following Liz Roche on LinkedIn at: https://www.linkedin.com/in/eroche1Follow Sarah Marzano on LinkedIn at: https://www.linkedin.com/in/sarahzmarzanoFollow Claudia Johnson on LinkedIn at: https://www.linkedin.com/in/claudia-johnson-b133436Follow Angela Myers on LinkedIn at: https://www.linkedin.com/in/angela-myers-2257aa1Follow Shweta Bhardwaj on LinkedIn at: https://www.linkedin.com/in/bhardwajshwetaFollow EMarketer online at: http://emarketer.comCPG Guys Website: http://CPGguys.comFMCG Guys Website: http://FMCGguys.comSheCOMMERCE Website: https://shecommercepodcast.com/Rhea Raj's Website: http://rhearaj.comLara Raj in Katseye: https://www.katseye.world/DISCLAIMER: The content in this podcast episode is provided for general informational purposes only. By listening to our episode, you understand that no information contained in this episode should be construed as advice from CPGGUYS, LLC or the individual author, hosts, or guests, nor is it intended to be a substitute for research on any subject matter. Reference to any specific product or entity does not constitute an endorsement or recommendation by CPGGUYS, LLC. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent.CPGGUYS LLC expressly disclaims any and all liability or responsibility for any direct, indirect, incidental, special, consequential or other damages arising out of any individual's use of, reference to, or inability to use this podcast or the information we presented in this podcast.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore the latest advancements shaping the future of drug discovery and patient care. Veradermics is making significant strides with its oral minoxidil formulation aimed at addressing female pattern hair loss. The mid-stage clinical trial results have analysts optimistic about Veradermics' potential to capture a significant portion of this underserved market. The oral form of minoxidil, traditionally used in topical Rogaine products, offers a novel delivery method that could enhance patient adherence and improve outcomes, marking an innovative leap in dermatological treatments. Johnson & Johnson is navigating the expiration of Stelara's patent protection with resilience, as Tremfya steps up to fill the revenue gap. With quarterly sales exceeding $2 billion, Tremfya underscores the critical role of strategic lifecycle management and robust product pipelines in weathering patent cliffs. This success highlights the necessity for pharmaceutical companies to sustain growth through a well-rounded portfolio that can absorb such impacts. In oncology, Celcuity has achieved a pivotal milestone with FDA approval for its small molecule inhibitor targeting breast cancer. This therapy promises blockbuster potential and could become a new standard-of-care, expanding treatment options for patients. The approval reflects ongoing innovation in oncology, where small molecules continue to play an essential role alongside biologics in advancing cancer therapies. AI-driven drug discovery is gaining traction as Insilico Medicine partners with CDMO Bora in a potentially $2.5 billion deal. This collaboration underscores AI's transformative potential in accelerating drug discovery and development processes. By leveraging artificial intelligence, Insilico aims to identify new drug candidates more efficiently, expediting their journey from bench to bedside. Kelun-Biotech is marking significant progress with its SAC-TMT program targeting non-small cell lung cancer (NSCLC), filling gaps left by Merck's phase 3 efforts. This development is crucial for providing more tailored therapeutic options in oncology, illustrating how advancements in drug development are driving forward personalized medicine. Roche continues its exploration of Alzheimer's disease treatments with a multifaceted approach that includes both amyloid and tau proteins as targets. While its phase 3 amyloid program is prominent, Roche's interest in tau protein highlights the complexity of tackling neurological disorders and the need for diverse therapeutic strategies. Meanwhile, Biogen remains steadfast in defending its anti-tau Alzheimer's candidate following mixed phase 2 results that showed slowed cognitive decline. Despite stock volatility, this endeavor illustrates the high-stakes nature of Alzheimer's research as companies pursue novel approaches to this challenging disease. Regulatory landscapes are also shifting as Johnson & Johnson halts development of an eye disease gene therapy after disappointing phase 2b results. This move reflects the inherent risks involved in gene therapy and underscores the necessity for thorough evaluation at each clinical stage. Medtronic's recall of its Harmony delivery catheter system due to potential detachment risks serves as a reminder of the paramount importance of safety and quality control in medical device manufacturing. Such recalls impact patient safety and emphasize regulatory vigilance over device reliability. In summary, these innovations demonstrate the dynamic nature of the pharma and biotech industries where cutting-edge science drives progress. Integrating AI into drug discovery, managing product lifecycles post-patent expiry, advancing personalized medicine, and maintaining regulatory diligence collectively shape a landscape focused on improving patient outcomes worldwide. Turning to recent scientific developments: Eli Lilly's presentation at AAIC 2026 on their anti-amyloid Alzheimer's drug Kisunla explores maintenance therapy possibilities once amyloid levels fall below a threshold. This potential shift could signify a paradigm change by extending therapeutic benefits and possibly improving long-term outcomes for patients with Alzheimer's. Biogen's advances with its anti-tau Alzheimer's therapy partnered with Ionis Pharmaceuticals further validate the tau hypothesis. The promising mid-stage data on their antisense drug Diranersen opens opportunities for other companies like Denali Therapeutics to explore similar avenues for treating neurodegenerative diseases. The industry is also witnessing a resurgence in biotech IPOs during 2026's first half, recovering from a sluggish 2025. This surge signals investor confidence in biotechnological innovation while providing capital for advancing research pipelines. Financial activities within the sector are robust as Attovia Therapeutics files for an IPO to fund its competitive pipeline against Sanofi's Dupixent. Meanwhile, Advancell's $315 million Series D funding supports advancing prostate cancer candidates into Phase 3 trials, backed by big pharma confidence in radiotherapy's potential. Lastly, regulatory transparency improves as the FDA resumes releasing drug rejection letters after a temporary pause—a move likely to influence future submissions significantly by offering clearer guidance on regulatory expectations. These developments collectively highlight how scientific innovation and strategic maneuvers transform pharmaceutical landscapes, promising profound impacts on patient care through advanced therapies and novel treatments worldwide. As these trends unfold, they reflect an industry increasingly reliant on technological integration and collaborations to drive future growth and innovation.Support the show

Do you have an Apple watch? Fitbit? Oura ring? Woop? Wearables have taken over in the past decade with claims that by constantly monitoring our heart rate, sleep, respiration, and activity, they can provide health data that can change your life. But is that really possible? Or even plausible? Marco Benitez, former professional athlete, and the Founder and CEO of ROOK joins us on the Living Well series today to talk all things wearables. He sees tremendous potential with how the data these tools compile can be utilized across all aspects of our lives, including in our cars (!), to change our behavior. But he acknowledges there's a catch. Many of these companies use the data collected not for YOUR benefit, but for theirs, and real change, well, there's no magic bullet. It's hard, takes time, and is all on you. Raised in Mexico with an insatiable curiosity and entrepreneurial spirit, Marco Benitez built his career at the intersection of health, technology, and sports science. Starting as a Tae Kwon Do champion, Marco's discipline and resilience guided him into biomedical engineering, then into high-stakes roles in pharmaceutical giants like Roche and Novartis. Here, he witnessed the transformative power of data in healthcare—and saw a profound opportunity to make health metrics more accessible and actionable. Determined to improve health management and bridge the gap between raw data and real impact, Marco co-founded ROOK.

In this episode, Dr. Vargo sits down with Dr. Elizabeth Roush, a practice owner from Northeast Indiana, to discuss the transformative impact of annual retreats on leadership, teamwork, and business growth. Dr. Roche explains the logistics, planning, and execution of successful annual retreats, sharing how they have become her staff's favorite day of the year. She delves into the themes, activities, and strategies that make these retreats effective, including team-building exercises, custom-tailored content, and the importance of fostering vulnerability and connection among staff. Dr. Roche also provides insights on maintaining the momentum of retreat learnings throughout the year for sustained improvements in practice operations and patient care. To register for Vision Forward, visit idoc.net to reserve your spot. 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest news and insights that are shaping the landscape of patient care and drug development. The U.S. FDA has expanded the label for Pfizer and Astellas' Padcev, in combination with Merck's Keytruda, to include all muscle-invasive bladder cancer patients. This significant regulatory update broadens access to a combination therapy that merges an antibody-drug conjugate with a PD-1 inhibitor, offering enhanced treatment options for patients unable to tolerate cisplatin, a common chemotherapy drug. The decision marks a pivotal step forward in providing more inclusive and effective treatment regimens for bladder cancer. In Scotland, Roche's Columvi has been endorsed by the Scottish Medicines Consortium for use in treating relapsed or refractory diffuse large B-cell lymphoma. This approval highlights the growing importance of bispecific antibodies in oncology, which can simultaneously engage two different antigens to enhance anti-tumor responses. Such innovations underscore the ongoing transformation of cancer treatment through combination therapies. Across the Atlantic, Health Canada has approved Clinuvel's Scenesse for erythropoietic protoporphyria (EPP), a rare condition causing extreme light sensitivity. Scenesse acts as a melanocortin receptor agonist, offering photoprotection and improving quality of life for those affected by this debilitating disorder. On the business front, Bayer's strategic partnership with Apollo has secured a €3 billion equity deal for its long-acting reversible contraceptives business. This move underscores a growing emphasis on women's health and contraceptive innovation. Likewise, CMS and Insilico's collaboration aims to harness artificial intelligence for CNS drug discovery, promising to accelerate drug development through AI-driven target identification. Clinical trials continue to reveal promising developments. Eisai's Etalanetug is showing potential in reducing tau tangle biomarkers in dominantly inherited Alzheimer's disease. Similarly, Eisai and BioArctic's Leqembi subcutaneous autoinjector demonstrates comparable efficacy to its intravenous counterpart, potentially improving compliance and accessibility for early Alzheimer's patients through less invasive administration methods. Financially, Apnimed is planning an IPO to support its sleep apnea pill's commercial launch, while Velogene Biotechnology has secured Series A funding to advance its gene-editing platform. These financial activities highlight ongoing investments in innovative solutions aimed at addressing unmet clinical needs. Yet, challenges persist as well. The FDA has rejected Hengrui and Elevar Therapeutics' combination treatment for hepatocellular carcinoma for a third time, emphasizing the difficulties of meeting regulatory standards and demonstrating efficacy. Additionally, Germany's new healthcare cost-saving law has doubled pharmaceutical rebate rates, sparking industry concern over potential impacts on profitability and innovation investment. The regulatory landscape continues to evolve with the FDA proposing streamlined registration processes under the "hub-and-spoke" model to enhance transparency and security within supply chains. Meanwhile, recent FDA transparency actions have led to the release of 14 drug rejection letters, underscoring ongoing challenges in securing approvals due to stringent regulatory requirements. Geographically, emerging biotech hubs like Basel and Beijing are gaining prominence as global talent hotspots due to their conducive environments for research and development collaboration. These regions are becoming increasingly attractive for biopharmaceutical innovation. Amid fierce competition in obesity management solutions, Lilly's launch of its oral GLP-1 receptor agonist Foundayo faces stiff competition from Novo Nordisk's Wegovy pill. The race reflects broader trends toward developing patient-centric therapies that offer convenience alongside therapeutic efficacy. Intellectual property strategies are also evolving as companies employ new patent tactics to maintain competitive advantages in crowded markets. Safety remains a top priority as exemplified by Lupin Pharmaceuticals' recall of contaminated eye drops, highlighting ongoing challenges in ensuring product safety. Lastly, advancements in wearable technology offer promising improvements in patient care; however, integration into clinical practice is met with infrastructural hurdles—a sentiment echoed by healthcare professionals surveyed by the AMA. Overall, these developments paint a complex picture of scientific innovation intersecting with regulatory evolution and strategic industry adaptations aimed at enhancing patient outcomes while navigating economic pressures. As the industry evolves, stakeholders must remain vigilant and adaptable to seize opportunities and address challenges effectively.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative updates and strategic shifts within the industry, reflecting both remarkable progress and inherent challenges. Sanofi's recent achievement marks a significant milestone in oncology with the FDA approval of Sarclisa Escena (isatuximab) as the first on-body injector for multiple myeloma treatment. This monoclonal antibody, targeting CD38, offers a novel subcutaneous delivery method, simplifying administration and potentially enhancing patient compliance by reducing the need for frequent clinic visits. This aligns with the industry's ongoing shift towards patient-friendly drug delivery systems, emphasizing convenience without compromising efficacy. In another promising development, GSK and Hansoh Pharmaceutical have reported positive results from their Phase 3 trial evaluating risvutatug rezetecan for small cell lung cancer. This antibody-drug conjugate, targeting B7-H3, has shown potential when combined with chemotherapy to extend patient survival. Given the aggressive nature of small cell lung cancer and limited treatment options, these findings underscore the potential of targeted therapies to improve clinical outcomes significantly. Forte Biosciences' FB102 also takes a spotlight in clinical advancements. In its Phase 1b trial for vitiligo, FB102 demonstrated a 45.8% placebo-adjusted benefit. This monoclonal antibody works by modulating immune responses through the IL-15 pathway via CD122, offering new hope for patients with this challenging autoimmune condition. On the regulatory front, ARPA-H's commitment of up to $160 million towards developing personalized genetic medicines for rare diseases is noteworthy. This investment is set to accelerate innovations in gene therapy and personalized medicine platforms. Such advancements promise to revolutionize pediatric care and extend beyond by tailoring treatments to individual genetic profiles, enhancing efficacy while minimizing adverse effects. Strategic collaborations continue to reshape the industry landscape. Rani Therapeutics' partnership with PegBio aims at advancing oral delivery systems for obesity and metabolic diseases. Similarly, Simcere Pharmaceutical's collaboration with Schrödinger leverages AI-driven drug discovery efforts. These alliances highlight an increased reliance on computational platforms to streamline therapeutic development processes. From a financial perspective, Mesoblast Limited reports substantial revenue from its cell therapy product Ryoncil, signaling strong commercial viability for cell-based treatments targeting rare diseases. Additionally, Cue Biopharma's successful $50 million fundraising underscores investor confidence in advancing therapies for immunological disorders. However, not all news is positive. Roche has decided to halt two programs targeting Huntington's disease due to inadequate efficacy and safety concerns. This decision reflects the complexities involved in developing effective treatments for neurological disorders—a field fraught with scientific challenges yet rich with potential rewards. In market dynamics, McKinsey's report advocates for a structural redesign of biopharmaceutical R&D to fully leverage AI's capabilities. This recommendation resonates with current industry trends focusing on strategic innovation to maximize efficiency and discovery potential. The FDA's third rejection of Hengrui Pharma and Elevar Therapeutics' combination therapy for liver cancer underscores the rigorous scrutiny such treatments face despite their promise in addressing complex cancers. In contrast, BioNTech's preparation to launch its HER2 antibody-drug conjugate (ADC) signifies its strategic pivot back towards oncology after mRNA vaccine successes. Bayer's decision to sell a minority stake in its contraceptives business demonstrates how companies are strategically realigning portfolios to focus on core areas while securing funding for innovation. This move reflects broader trends within pharma as companies navigate financial landscapes to support long-term research goals. Amid these developments, regulatory environments continue evolving. NICE's stance against future Lumakras reimbursement in the UK highlights ongoing challenges in balancing cost-effectiveness with access to innovative therapies. Meanwhile, ARPA-H's significant funding allocation signals robust governmental support for advancing precision medicine within genetic therapies. In conclusion, today's updates reveal an industry characterized by a relentless pursuit of innovation amidst complex regulatory landscapes. As companies navigate these dynamics through strategic collaborations and scientific breakthroughs, their efforts hold promise for enhancing patient care across diverse therapeutic areas globally. Stay tuned as we continue to track these exciting developments shaping the future of pharmaceuticals and biotechnology. Thank you for tuning into Pharma Daily—your go-to source for up-to-date insights from the world of pharmaceuticals and biotechnology.Support the show

This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the industry’s major scientific meetings of the summer. First, we discuss Vertex’s $10 billion acquisition of Crinetics Pharmaceuticals, the company’s largest deal to date, and what it says about Vertex’s push beyond its historic strength in cystic fibrosis. We also cover growing scrutiny from U.S. lawmakers over the industry’s use of clinical trials in China. Then, Fierce Pharma Senior Editor Fraiser Kansteiner recounts his recent trip to New Orleans for the American Diabetes Association’s 2026 Scientific Sessions with Fierce Pharma Marketing’s Zoey Becker. For years, ADA has focused heavily on its eponymous indication, but this year’s meeting made clear how much the conversation is evolving, with obesity data from drugmakers of all stripes taking up more of the spotlight. Topics include the biggest data sets from the meeting, what it was like to sit down with Novo Nordisk’s new CEO for the first time and the latest from Insulet’s Marvel collaboration on a line of comics about an Omnipod-wearing superheroine. To learn more about the topics in this episode: Vertex, in its largest-ever deal, acquires endocrine disease specialist Crinetics for $10B As US lawmakers increase scrutiny of Chinese trials, industry fears ‘huge distraction and expense’ ‘I’m a lot more optimistic today’: Mike Doustdar tells Fierce about pivotal first year as Novo Nordisk CEO ADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes ADA: Amgen highlights Repatha perks, GLP-1 pitfalls in push to boost cardiometabolic pedigree With ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race ADA: Novo's Wegovy pill reaches new GLP-1 patients with impressive 3M prescription milestone ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect ADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 update ADA: Lilly posts oral semaglutide-topping data as Foundayo speeds toward 2nd potential nod in diabetes This week's episode is sponsored by IQVIA Biotech. Built for biotech innovators, IQVIA Biotech is a full-service CRO, designed for agility, fast decisions, and the urgency needed for emerging biopharma. With dedicated teams and deep therapeutic expertise, we help move programs forward with focus and confidence. Visit IQVIABiotech.comSee omnystudio.com/listener for privacy information.

Karl Darlow and Andrey Santos are signing for United as the summer starts to feel like the last under Mourinho; no worries, we have a shiny stadium update to distract us from all that. Hosted on Acast. See acast.com/privacy for more information.

Many corporate marketing strategies face dropping conversion tracking metrics because they rely on closed ad-tech vendors that introduce platform bias into campaign attribution. Mathieu Roche, co-founder and CEO of ID5, breaks down how to construct neutral identity infrastructure to protect cross-channel addressability and secure reliable measurement.He shares his operational playbook for navigating the shift toward agentic advertising, altering data graphs to track automated consumer assistants, and using internal team hackathons to automate routine sales and CRM processes.Key tactical themes covered:Building neutral identity channels to protect unbiased attribution tracking.Modifying data graphs to track verified virtual agents across the purchase funnel.Shifting identity tech priorities from baseline audience targeting to outcome measurement.Linking automated AI transactions directly back to programmatic ad investments.Utilizing structured team sprints to automate routine operational follow-up tasks.Mathieu Roche is the co-founder and CEO of ID5, directing un-siloed identity architecture and multi-platform validation systems for leading digital publishers.Connect with our guest:Follow Mathieu Roche on LinkedIn: https://www.linkedin.com/in/mathieuroche/Explore ID5 Solutions: http://id5.ioOptimize Performance Advertising with Strike Social: https://strikesocial.com/guaranteed-paid-social-media-ads-outcomes/Connect with Host Dylan Conroy: https://www.linkedin.com/in/dylanconroy/

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and challenges shaping the landscape of these dynamic sectors. Starting with Ipsen's Dysport, which has made notable strides in its Phase 3 trials for migraine prevention. The trials covered both episodic and chronic conditions, marking a first in the neurotoxin market. Dysport's success positions it as a formidable competitor to AbbVie's Botox, expanding therapeutic options for individuals battling migraine disorders. This achievement showcases the potential efficacy of botulinum toxin-based therapies in neurology and pain management, offering promising new avenues for patient care. In regulatory news, Boehringer Ingelheim has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for Jascayd, a small molecule PDE4B inhibitor with antifibrotic properties. This approval marks a significant milestone in the treatment of idiopathic and progressive pulmonary fibrosis. Jascayd's addition to the therapeutic arsenal offers new hope for managing this debilitating condition, emphasizing the ongoing efforts to improve patient outcomes through innovative treatments. The arena of business development sees HanChorBio partnering with InxMed to advance oncology research. By combining HCB101 with FAK inhibitors and FAP-targeted ADCs, this collaboration aims to leverage antibody and small molecule drug discovery techniques. The goal is to develop innovative cancer treatments that could redefine therapeutic approaches in oncology. Keenova Therapeutics has also reported success with Xiaflex for plantar fibromatosis. This enzyme injection therapy offers a novel approach by targeting collagen, thus providing an innovative solution for musculoskeletal conditions. Similarly, Fate Therapeutics' FT819, an off-the-shelf CAR-T therapy, has shown early promise in tackling treatment-resistant systemic sclerosis, underscoring the potential of cell therapies beyond oncology. Meanwhile, MindRank's successful Series B funding round of $52 million highlights the growing role of AI platforms in drug discovery. The funding will propel its AI-discovered oral GLP-1 obesity pill into Phase III trials, exemplifying how technology-driven solutions are gaining traction in addressing metabolic diseases like obesity. On the regulatory front, Saol Therapeutics has resubmitted SL1009 (DCA) to the FDA for pyruvate dehydrogenase complex deficiency. This submission underscores ongoing efforts to address rare metabolic disorders using small molecule therapies. Additionally, Sanofi's concessions to the EU regarding flu vaccine marketing illustrate the complexities of competitive dynamics and regulatory scrutiny within the vaccine market. However, not all developments are favorable. AstraZeneca and Ionis Pharmaceuticals faced a setback as their drug Wainua failed its Phase 3 trial for transthyretin-mediated amyloid cardiomyopathy. This outcome highlights the challenges inherent in developing effective treatments for complex cardiovascular conditions. Meanwhile, regulatory processes remain contentious as the FDA pauses its release of complete response letters amid debates over proprietary information disclosures. In another noteworthy development, GSK has terminated its $2.2 billion collaboration with Alector after underwhelming results from Alzheimer's drug trials. This decision highlights both financial implications and strategic shifts as companies reassess risk tolerance in neurodegenerative disease research. Conversely, Roche's success with its KRAS G12C inhibitor divarasib in Phase 3 lung cancer trials underscores the promise of precision medicine. Divarasib outperformed competitors Amgen's Lumakras and Bristol Myers Squibb's Krazati, positioning Roche to potentially redefine standards of care based on genetic profiles. In a move reflecting industry trends towards collaboration and innovation risk-sharing models, AstraZeneca has partnered with Sino Biopharmaceutical on respiratory disease research. This strategic alliance represents a substantial investment aimed at expanding AstraZeneca's pipeline in respiratory therapeutics. Lastly, amidst these developments, psychedelic drugs are experiencing a renaissance in psychiatric care. Companies like Compass Pathways are pioneering clinical validation for their use in treating depression, signaling a potential paradigm shift from traditional SSRIs to newer therapeutic classes pending safety and efficacy data. Overall, these stories illustrate a dynamic interplay of scientific progress and regulatory navigation within the pharmaceutical and biotech sectors. While challenges persist—particularly in neurodegenerative disease treatment—the breakthroughs in oncology and metabolic disorder therapeutics offer hopeful prospects for improving patient care. As these industries continue evolving, integrating advanced technologies such as AI will likely play a pivotal role in shaping future therapeutic landscapes.Support the show

People are living longer than ever before and the science helping us live healthier for longer is advancing at a rapid pace. From AI-powered drug discovery and personalised medicine to GLP-1s and the longevity economy, this episode explores the trends reshaping healthcare, the companies leading the charge, and how investors can gain exposure to one of the world's fastest-growing industries.In this episode:00:00 – Why longevity is becoming a major investment theme03:16 – The $3.5 trillion biotech opportunity & the rise of the longevity economy07:58 – AI, peptides & personalised medicine driving medical breakthroughs14:56 – The risks: regulation, clinical trial failures & tariffs17:47 – Partner message from ANZ Business Start Right19:22 – The biggest opportunities in biotech over the next decade20:25 – The companies leading the biotech revolution27:13 – ETFs and how to invest in Biotech & LongevityStocks & ETFs Mentioned: CSL (ASX: CSL), Pfizer (NYSE: PFE), Merck (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), Roche, AstraZeneca (LSE: AZN), AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), Vertex Pharmaceuticals (NASDAQ: VRTX), Regeneron Pharmaceuticals (NASDAQ: REGN), Moderna (NASDAQ: MRNA), BioNTech (NASDAQ: BNTX), Unity Biotechnology (NASDAQ: UBX), BioAge Labs (NASDAQ: BIOA), Recursion Pharmaceuticals (NASDAQ: RXRX), ResMed (ASX: RMD), Cochlear (ASX: COH), Sonic Healthcare (ASX: SHL), Pro Medicus (ASX: PME), Telix Pharmaceuticals (ASX: TLX), Mesoblast (ASX: MSB), VanEck Global Healthcare Leaders ETF (ASX: HLTH), iShares Global Healthcare ETF (ASX: IXJ), Betashares Global Healthcare Currency Hedged ETF (ASX: DRUG), iShares U.S. Pharmaceuticals ETF, iShares Biotechnology ETF (NYSEARCA: IBB), SPDR S&P Biotech ETF (NYSEARCA: XBI), ARK Genomic Revolution ETF (BATS: ARKG), Range Cancer Therapeutics ETF (CANC)This episode ofThe Decade Ahead is brought to you by ANZ Business Start Right.———Want to get involved in the podcast? Record a voice note or send us a messageAnd come and join the conversation in the Equity Mates Facebook Discussion Group.———Want more Equity Mates? Across books, podcasts, video and email, however you want to learn about investing – we've got you covered.Keep up with the news moving markets with our daily newsletter and podcast (Apple | Spotify)We're particularly excited to share our latest show: Basis PointsListen to the podcast (Apple | Spotify)Watch on YouTubeRead the monthly email———Looking for some of our favourite research tools?Download our free Basics of ETF handbookOr our free 4-step stock checklistFind company information on TIKRResearch reports from Good ResearchTrack your portfolio with Sharesight———This podcast is intended for education and entertainment purposes only. Any advice is general advice and has not taken into account your personal financial circumstances. Before acting on general advice, you should consider if it is relevant to your needs. If unsure, speak to a financial professional. The host of this podcast and their guests may have positions in the companies mentioned. Equity Mates Media is part of the Betashares Group but maintains editorial independence and operates under Australian Financial Services licence 540697. Hosted on Acast. See acast.com/privacy for more information.

Pa the piper also joined Tom on the line, both were in good spirits ahead of their trip to Dublin tomorrow.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of remarkable advancements and strategic maneuvers that are shaping the future of drug development and patient care. Starting with Roche's breakthrough in oncology, their small molecule inhibitor, Divarasib, has shown promising results in a Phase 3 trial for patients with KRAS G12C-mutated non-small cell lung cancer. This trial demonstrated superior efficacy over competitors like Amgen's Lumakras and Bristol-Myers Squibb's Krazati. Historically, KRAS mutations have been difficult to target, but Divarasib's success underscores the potential of precision medicine in oncology. These findings could lead to more effective treatment options for NSCLC patients, showcasing how targeted therapies are revolutionizing cancer treatment by focusing on specific genetic mutations. In regulatory news, Vertex Pharmaceuticals has made significant strides with Casgevy (exagamglogene autotemcel), a gene therapy that now includes pediatric patients with sickle cell disease and transfusion-dependent beta thalassemia in its FDA-approved label. This marks a pivotal moment for gene therapy applications in blood disorders. Utilizing CRISPR technology, Vertex offers potentially curative solutions for debilitating conditions, signaling a new era where genetic disorders can be addressed at their root cause. Similarly, Novartis has gained European Commission approval for Itvisma to treat 5q spinal muscular atrophy in patients aged two years and older, further cementing gene therapies' role in mainstream medical practice. Strategic partnerships remain essential in driving innovation. Takeda's collaboration with Insilico Medicine on AI-driven drug discovery is a case in point. The $600 million partnership highlights the growing reliance on AI and machine learning to expedite therapeutic development processes. Platforms like Pharma.AI are being leveraged to identify novel drug candidates more efficiently. Additionally, AstraZeneca's alliance with CSPC Pharmaceutical Group to develop siRNA-based therapies for kidney diseases reflects the burgeoning interest in RNA therapeutics as these technologies open new avenues to address complex diseases. On the financial front, BridgeBio's ability to attract $1 billion in convertible preferred equity from Sixth Street and Healthcare Royalty underscores investor confidence in rare disease therapeutics. This funding will bolster its pipeline targeting cardiovascular and rare conditions, emphasizing the profitable potential found within niche markets of the pharmaceutical landscape. Manufacturing is also seeing expansion as Lonza deepens its partnership with an unnamed U.S. drugmaker to enhance biologics programs. Anticipated investments reaching into multi-billion Swiss Francs underscore the critical importance of robust manufacturing infrastructure to meet growing demands for biologics and antibody-drug conjugates. Clinical trials continue to yield promising results. Can-Fite Biopharma's Phase 2a trial for Namodenoson in treating advanced pancreatic ductal adenocarcinoma has shown promising survival data when combined with therapies targeting Wnt/β-catenin signaling pathways. At the same time, Otsuka's Phase 3 data for Voyxact (sibeprenlimab-szsi) demonstrated improved kidney function in patients with immunoglobulin A nephropathy, bolstering traditional FDA approval pathways. On the acquisitions front, GNI Group's acquisition of Ayumi Pharmaceutical for approximately JPY 44.8 billion highlights strategic moves to enhance global biopharma operations focusing on pain management solutions. Yet not all news is positive; Sanofi's Genzyme Ireland unit received an FDA warning letter regarding manufacturing violations related to Altuviiio production, pointing to ongoing regulatory challenges within production practices. Moving on to geopolitical considerations, recent congressional letters to major pharmaceutical CEOs have raised concerns about clinical trials conducted within China due to national security concerns. This tension illustrates the delicate balance between leveraging China's economic potential and safeguarding US interests—a critical issue as international collaborations continue to expand. Meanwhile, AstraZeneca's ongoing collaborations with CSPC Pharmaceutical Group further signify strategic bets on China's capabilities despite geopolitical tensions. Their joint efforts focus on kidney disease treatments while adding to existing agreements addressing obesity and chronic diseases. The FDA remains pivotal as key decisions anticipated this quarter could significantly influence investment strategies and research priorities. This includes revisiting applications previously delayed or rejected—decisions that could reshape industry dynamics. In conclusion, this dynamic landscape is marked by significant scientific breakthroughs and complex global interactions guiding pharmaceutical and biotech sectors toward a transformative era. Gene therapy advancements underscore progress in personalized medicine while geopolitical factors continue influencing strategic industry decisions. As regulatory bodies evolve their approaches alongside increasingly international partnerships, these developments collectively herald profound implications for drug development and patient care globally.Support the show

In this episode I'm joined by Art de Roche to talk about Arsenal at the World Cup, and the ongoing concerns around Declan Rice who looked physically shattered throughout England's 2-1 win over DR Congo. We then chat about how the price of the average midfielder has risen so highly with some high profile, high price deals going through this week, and how that might influence what the club need to do this summer. I also ask if this window needs Arsenal to make a 'statement' signing, such as PSG winger Bradley Barcola, using the pull from being Champions and Champions League finalists to bring in the calibre of player who can really help us retain the title and go one better in Europe. There's also a link to a back-up goalkeeper, some thoughts on Santi Cazorla after he announced his retirement, and lots more.Here's the Sid Lowe interview with Santi Cazorla mentioned in the pod - https://www.theguardian.com/football/2018/sep/07/santi-cazorla-villarreal-injury-arsenal-interview-sid-lowe

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of the pharmaceutical and biotech sectors, where significant scientific advancements, regulatory shifts, and strategic business maneuvers are reshaping patient care and therapeutic approaches. A pivotal moment recently unfolded with Ipsen's acquisition of Kartos Therapeutics for up to $1.75 billion. This strategic move adds navtemadlin, a promising myelofibrosis candidate, to Ipsen's oncology pipeline. Navtemadlin is a small molecule inhibitor targeting MDM2, a crucial regulator of the tumor suppressor p53. This acquisition reflects a strategic emphasis on expanding therapeutic options in hematologic oncology, aiming to improve outcomes for patients with myelofibrosis—a rare and debilitating bone marrow disorder. In regulatory advancements, Viridian Therapeutics achieved a significant milestone with FDA approval of Lumvoa (veligrotug-vvze) for treating thyroid eye disease across both active and chronic stages. This monoclonal antibody targets IGF-1R, addressing an unmet need in autoimmune conditions by potentially altering disease progression and improving patient quality of life. Concurrently, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) secured EU approval for HER2-positive metastatic solid tumors after successful Phase 2 trials. Enhertu's role as an antibody-drug conjugate highlights a breakthrough in targeting cancer cells more precisely while sparing healthy tissues, underscoring the growing importance of personalized medicine in oncology. The clinical trial landscape saw pivotal results with AstraZeneca's efzimfotase alfa demonstrating efficacy in Phase 3 trials for hypophosphatasia—a rare bone disease characterized by defective bone mineralization due to enzyme deficiencies. This protein therapy aims to replace deficient alkaline phosphatase enzymes, offering hope for improved skeletal outcomes in affected children. Furthermore, BridgeBio Pharma's infigratinib showed promise in Phase 3 trials for treating achondroplasia by demonstrating significant growth improvements. As a fibroblast growth factor receptor (FGFR) inhibitor, it underscores the potential of targeted therapies in addressing genetic disorders. On the business development front, Zymeworks' acquisition of Theravance for $929 million adds the COPD drug Yupelri to its portfolio alongside lucrative royalty arrangements. Yupelri is a long-acting muscarinic antagonist (LAMA) that offers once-daily bronchodilation for COPD patients. This strategic move bolsters Zymeworks' respiratory franchise and highlights the ongoing consolidation trend in the industry as companies seek growth through diversification and enhanced therapeutic offerings. In parallel, Talawar Therapeutics is planning a $285 million SPAC merger to advance its bispecific antibody for eczema treatment. Similarly, Lycia Therapeutics raised $75 million in Series D funding to progress its extracellular protein degrader pipeline aimed at autoimmune diseases. These investments signal robust interest in novel modalities such as bispecific antibodies and targeted protein degradation technologies that promise new therapeutic avenues. However, not all news was positive. The FDA rejected Sobi's NASP (pegadricase) application due to manufacturing issues, highlighting ongoing challenges firms face in meeting regulatory standards for complex biologics. Additionally, Evommune's Evo756 failed its primary endpoint in Phase 2b trials for chronic spontaneous urticaria, illustrating the high-risk nature of drug development. Looking at the broader industry trends, Roche's launch of Axelios 1 represents a strategic push into the gene sequencing arena, directly challenging Illumina's market dominance. As precision medicine continues to gain traction, advancements in gene sequencing technologies are likely to play an instrumental role in personalized medicine strategies, offering more tailored treatment options based on genetic profiles. Finally, we see significant shifts driven by recent regulatory changes and scientific breakthroughs across the sector. The FDA's revised stance on rare disease drug approval criteria could expedite processes for companies like Skyhawk Therapeutics and Biohaven, providing new opportunities to bring treatments to market more swiftly. These regulatory adjustments reflect an evolving landscape where innovation is poised to meet unmet medical needs more efficiently. In conclusion, these developments underscore a dynamic pharmaceutical and biotech landscape characterized by strategic acquisitions, regulatory successes, and scientific advancements aimed at addressing complex diseases with innovative therapies. As these sectors continue to evolve, stakeholders must navigate a complex interplay of technological advancements, regulatory scrutiny, and competitive pressures to drive meaningful advancements in healthcare outcomes. Stay tuned with Pharma Daily as we continue to explore these significant shifts shaping the future of healthcare and drug development. Thank you for joining us today as we unpack these pivotal stories impacting our industry.Support the show

Elle s'appelle Elisa Deroche, Raymonde de Laroche ou encore la Baronne de Laroche. Elle est à la fois une et multiple mais à l'aube du XXe siècle, tout son être est tendu vers un seul objectif : la conquête du ciel. C'est ainsi qu'elle va s'imposer comme la première véritable femme-pilote au monde. Un destin hors normes, entre grandes joies et grandes tragédies.Embarquez pour un fascinant voyage dans le temps à l'aube de l'aviation ! Suivez les aventures extraordinaires d'Elisa de Roche, cette femme audacieuse qui a bravé tous les obstacles pour devenir l'une des premières aviatrices au monde. Jeune femme libre et passionnée de mécanique, Elisa Deroche va peu à peu se faire un nom dans le milieu naissant de l'aéronautique. Malgré les réticences de son entourage, elle va résolument prendre les commandes d'un avion et s'élever dans les airs, devenant ainsi une véritable star de l'époque. Les journaux se disputent ses exploits, la surnommant tour à tour 'la baronne de l'air' ou 'le petit oiseau'. Mais son ascension fulgurante est aussi marquée par de terribles épreuves. La mort brutale de sa fille, puis celle de son mentor, vont profondément la bouleverser. Malgré les dangers, elle ne cessera pourtant de repousser les limites, décrochant records sur records. Jusqu'à ce tragique accident qui mettra fin à sa carrière d'aviatrice.Plongez dans l'épopée captivante d'une femme hors du commun, qui a su s'imposer dans un monde d'hommes et écrire une page de l'histoire de l'aviation.

A dash of mystery, a sparkle of magic, and all things cozy! Elle interviews fellow cozy authors in this bookish podcast from Authors on the Air. Happy Pride Month! Today on the podcast, meet Máire Roche, aka Mary E. Roach, author of Bromantasy and more! Elle and Mary talk about writing stories to uplift the community, choosing joy in dark times, and including injustice in cozy tales. Happy listening! Mary's Bio: Mary E. Roach is a former teacher who now writes across genres and age categories, including young adult thrillers, romantic suspense, romantasy, and middle grade fantasy. When she is not writing stories for and about powerful women, Mary enjoys running, teaching martial arts, and disappearing into the wilderness. Mary lives in St. Paul with her wife and their very disagreeable cat. Find Mary and Her Books Online: https://www.maryeroach.com/ ~~~ Elle's Bio: Elle Hartford writes cozy mystery with a fairy tale twist. The award-winning first book in her Alchemical Tales series, Beauty and the Alchemist, finds amateur sleuth Red mixed up with murderous beasts and moody beauties, and a set of missing books besides! Elle has also written two spin-off series, the cozy fantasy-goes-to-the-beach Marine Magic series as well as Pomegranate Cafe Romance. For other writers and authors looking into “wide” indie publishing, check out the Beyond Writing blog (ellehartford.substack.com) with how-tos, resources, and back episodes of the Cozy Alchemy podcast. Find Elle Online: https://ellehartford.com

Today, I am excited to speak with Stephan Roche, a Partner at BanyanGlobal, a family enterprise advisory firm. Stephan joined the firm after more than a decade as a family office and investment executive. Most recently, he was CEO of Walton Enterprises, the family office for the Walton family. He also served as COO for Cascade Asset Management, the private investment office for Bill Gates and the Gates Foundation. An inaugural member of the UChicago Booth School's Family Office Initiative advisory board, Stephan also serves on the boards of Silver Ventures, a family-owned enterprise based in San Antonio, TX, and Guidant Financial Group, a closely held small business financial services firm based in Boise, Idaho. Stephan's expertise is in family enterprise governance, family office strategy, and family wealth stewardship. Stephan worked with some of the most successful and influential families in the world and has had the opportunity to analyze the ingredients of their enduring success. He shares his experience on what it takes to create a durable family enterprise. Stephan points out that durable family enterprises need to strike the right balance between their focus on financial capital vs. human capital. He talks about the importance of this balance, and especially the significance of human capital for the long-term success of family offices and enterprises. An important dimension for families in their quest for a durable enterprise is their philosophical and practical stance towards technology. Stephan explains how technology plays into the professionalization and sustainability of the family enterprise and family office and how families can best align their adoption of frontier technologies, such as AI, with their shared values and purpose. Another important practical dimension that each family enterprise must deal with almost constantly is leadership succession. Stephan provides important leadership succession tips and lessons he would offer families who are striving to build a durable family enterprise. Do not miss this deeply informative conversation with one of the veteran operators, leading advisors, and prominent thought leaders in the enterprise family wealth and family office space.

This episode covers: Cardiology This Week: A concise summary of recent studies Host: Emer Joyce Guests: Yasmina Bououdina, JP Carpenter, Milton Packer, Lorenz Raeber Want to watch that episode? Go to: https://esc365.escardio.org/event/2558 Want to watch that extended interview on PCI guidance by intracoronary imaging, go to: https://esc365.escardio.org/event/2558?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Milton Packer has declared to have potential conflicts of interest to report: 89bio, Abbvie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, ARMGO, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Daiichi Sankyo, Imara, Lilly, Medtronic, Moderna, Novartis, NovoNordisk, Pharmacocosmos, Regeneron, Roche, Salamandra. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Lorenz Raeber has declared to have potential conflicts of interest to report: consultation/speaker fees from Abbott, Boston Scientific, Occlutech, and research grants to the institution by Abbott, Heartflow, Novo Nordisk and Heartflow. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Everyone collects weak signals now. Most of what they collect predicts nothing. A weak signal isn't a thing you spot, it's a prediction you make, and the edge goes to whoever bets on it while being wrong is still cheap. So how do you become the one placing the bet, not the one still collecting reports? Let's get into it. What a Weak Signal Actually Is A weak signal is a faint piece of evidence that points to something a customer will want before they can name it, and before the market has priced it in. Faint, because if it were loud, everyone would already be acting on it. Deniable, because you can always explain it away as noise, and most people do. That deniability is the whole point. The moment it becomes undeniable, the advantage is gone and the price has moved. Why Noticing Stopped Being the Edge Ten years ago, noticing was hard. You needed sources, a network, time to read widely, a feel for the edges of your industry. That was the moat. It isn't anymore. Every team has a trend report and three newsletters and an AI tool surfacing emerging behaviors on a schedule. The noticing got automated. What didn't get automated is the judgment about which signal predicts a structural change and which points to nothing real, and the nerve to act early. Inside Roche's Innovation Board I sat on Roche's diagnostics innovation board, the only outsider in the room, helping decide which ideas got funded. At one point we took on diabetes care. I am not diabetic. So I had Roche ship me every meter and test strip they made, and I pricked my finger up to a dozen times a day to feel what their customers felt. You cannot innovate for a customer whose day you have never lived. Skip that, and everything after is a guess. Roche was a leader in blood glucose testing with its Accu-Chek meters, and the math looked obvious. Someone with type 1 diabetes tests around eight times a day, every day, for life. A big, stable business. Type 2 was the smaller story per patient. Those patients tested once, maybe twice a day, so each one looked worth less, and we filed the category under "less interesting." We could already see type 2 climbing. We weighed it against the per-patient math and explained it away. Then type 2 diagnoses exploded into one of the fastest-growing chronic conditions in the world. And the category stopped being about counting tests per day at all, because monitoring went continuous, the always-on sensors people wear today. We had seen the early edge of both shifts. We even predicted them. We just didn't move fast enough, and the reason is the one that kills most weak signals inside a big company. Project approval and annual budgets are built to fund what's already proven, not to chase something still faint. Roche got there. Accu-Chek SmartGuide, its real-time continuous monitor, is on the market now. I just wish we had moved the moment we saw it, instead of waiting for the next budget cycle to make it safe. How to Read a Weak Signal We didn't miss the type 2 signal for lack of noticing. We noticed. We missed it on the three things that come after, and those you can train. The moves start once you've got a signal you can't quite dismiss, and the skill is what you do with it. Tell the Canary From the Costume A canary in a coal mine matters because the air changed. It signals something structural, a shift in the environment that affects everyone in it, whether they've noticed yet or not. A costume is the opposite. A few people put it on, it's striking, it spreads for a season, then they take it off and the room is exactly as it was. On day one the two look identical. A behavior appears, it's unusual, it's spreading. The only question that matters is whether it predicts a change a customer can't reverse, or a moment that will pass. Back in 2018 I wrote about telling a trend from a fad, and the test still holds: ask what need the behavior reveals. Type 2 was a canary, and we read it as a costume, because we counted testing frequency instead of the need underneath it. That need, millions of people learning to manage a lifestyle disease, only grew. The discipline is refusing to let the size of the spike tell you which one you're looking at. Costumes spike too, sometimes higher. You're reading for the need, not the noise. Read the Window A signal's window is short. Too early, you can't tell it from noise and you waste resources chasing ghosts. Too late, it's obvious, everyone sees it, and the advantage is already priced in. The value lives in the narrow gap between. Waiting for more evidence feels like better judgment, but the evidence that finally convinces you has already reached your competitors. Certainty and advantage move in opposite directions, so by the time you're sure, sure is just another word for too late. The question isn't whether the signal is real yet. It's how much longer you can be the only one taking it seriously. Act While Being Wrong Is Cheap This is the move that separates the people who read signals from the people who collect them, and almost nobody is willing to make it. A signal you predict but never act on is still just watching. Ideas without execution are a hobby, and I'm not in the hobby business. The whole value of an early signal is that you move before it's confirmed. Wait for proof and you've waited too long. So you act on thin evidence. And thin evidence is wrong a lot, which means you will be wrong a lot. People hear that and freeze, because they picture the cost of being wrong as the failed product, the wasted year, the budget burned on a guess. People call that caution. It isn't. The skill is structuring the bet so that being wrong is cheap. You don't commit a product line to a deniable signal. You commit a prototype. A landing page. One conversation with ten customers. A two-week test that costs you a sprint and buys you information you can't get any other way. Being early and wrong should cost you a week. Being early and right should put you a year ahead. You're not betting on being right. You're buying the option to be right, cheap enough that being wrong doesn't hurt, and you scale up only as the signal firms up. That's why the noticing crowd never gets here. Noticing carries no risk, so it never builds the muscle for cheap commitment. They watch, they report, they wait for certainty, and they call it foresight. It's the safe choice, and it's worth nothing. Practice Exercise: Run a Signal Through All Three Pick one behavior you've been dismissing as noise. Something you've seen more than once, in your customers, your kids, your own habits, that you waved off because it looked too small or too strange to matter. Then run it through the three moves. Canary or costume. What need does the behavior reveal? A need the person can't go back from, or a novelty they'll set down in a season? Write the answer in one sentence. If you can't, you don't understand the signal yet. Find the window. How much longer does this stay deniable? Who else is likely seeing it? If the honest answer is "it already feels obvious," pick a different signal. You're late on this one. Design the cheap bet. What's the smallest thing you could do this month to test whether you're right, where being wrong costs a week and being right puts you ahead? Name the bet. Name the cost. Name what you'd learn. Do this with one real signal and you'll feel the difference between collecting signals and using them. Collecting is comfortable. Using one costs you a decision. If you want a sparring partner for that, I built one. From Signal to Bet is a set of AI prompts that run a signal through these same three moves and argue with your read at each one. It's free at innovation.tools. The exercise teaches you the moves. The prompts make you defend them. The signal was always there, for you and for everyone reading the same reports you read. The edge was never in seeing it. It was in what you were willing to do before it was safe to do anything at all. Get good at that, and you stop reacting to the future and start arriving early.  

Networking gets a bad reputation. And honestly? It's earned it.For most people, the word conjures images of awkward small talk, business cards nobody keeps, and conversations that feel more like auditions than actual human connection. It feels transactional. It feels fake. And for a lot of women, especially, it feels like a game they were never taught how to play.But what if the problem isn't networking itself — it's the way we've been taught to think about it?On the 2B Bolder Podcast, host Mary Killelea sits down with Monique Kelley — professor, consultant, and author of Redefining Networking: How to Lead with Your Unique Value, an Amazon #1 Bestseller in Business Ethics — to completely reframe what networking is, what it isn't, and why getting it right might be the single most important career move you make.Monique is a two-time PRNEWS Top Women in PR award recipient, a founding member of CHIEF, and has been featured in FOX and Fast Company. She's built a career working with some of the biggest names in biopharma — Pfizer, Roche, Lilly, Johnson & Johnson — not by chasing opportunities, but by building meaningful relationships that opened doors long after the conversation ended. Today she teaches the only Career Readiness course at Boston University's College of Communication, shaping how the next generation of professionals show up, connect, and lead.This conversation covers it all — her career journey from a pre-med detour into communications and healthcare PR, the moment she stepped in to present to a major client when her boss was out and realized that relationships matter just as much as the deck, and the pivots that took her from agency life to in-house roles to fractional consulting and eventually the classroom.Mary and Monique dig into the real stuff:What most people fundamentally get wrong about networking — and why that misunderstanding is costing them real opportunitiesWhat "leading with your value" actually means in practice, not just as a concept but as a daily behaviorA clear, three-step framework for defining your unique value, choosing the right audience, and showing up consistently — on LinkedIn and beyondWhy your network isn't a list of contacts. It's a living system of people who understand what you bring and actively want to advocate for youHow to build a network from scratch when you feel like you have nothing to offer and nowhere to startWhy remote work and meeting overload are making organic connection harder than ever — and what to do about itThe truth about "I don't have time to network" (spoiler: it's a prioritization issue, not a time issue)What Monique is seeing right now across executives, students, and mid-career professionals — and the specific behaviors she notices in women who are actually building momentumWhat she teaches her Career Readiness students at BU that experienced professionals desperately need to hearAnd the one thing she wishes she had understood earlier about building a career that lastsWhether you're in the middle of a career transition, feeling stuck in a role that no longer fits, or just dreading the next industry event — this episode will completely shift how you think about connection, value, and what it actually means to build a career on your own terms.

This week on the Long Island Tea Podcast, Stacy and Sharon catch listeners up on their recent adventures across Suffolk County, from delivering Suffolk 250 Passports to local students and attending the U.S. Open at Shinnecock Hills to teasing several exciting remote podcast recordings coming up in the weeks ahead. They also dive into the stories shaping summer on Long Island, including the growth of beloved community events, waterfront destinations, maritime history, Fire Island's cultural significance, Long Island's thriving food scene, and the people helping make the region such a special place to live, work, and visit.#ShowUsYourLongIslanderThis week's spotlight features Mike McElwee of the Bay Shore Restaurant Committee, who reflects on the remarkable growth of Alive by the Bay as the event enters its ninth summer season. Mike shares how the initiative began in 2017, the impact it has had on the Bay Shore community, and what visitors can look forward to during this year's events on June 30, July 14, July 28, and August 11.Show us YOUR Long Islander by sending us a DM or emailing spillthetea@discoverlongisland.com.#LongIslandRevolutionaryRootsThis week we're taking to the water with the arrival of the Liberty Clipper in Port Jefferson Harbor. The 125-foot traditionally rigged tall ship is now offering sailing excursions through the end of June before participating in America's 250th Anniversary Tall Ships Parade. We also spotlight the return of the historic Selina II to the East End, bringing a century of Long Island maritime history back home.#LongIslandLifeWe're discussing the opening of Faraway Sag Harbor, a newly reimagined waterfront hotel bringing fresh energy to one of Long Island's most beloved villages.We also celebrate the Knicks' championship run and the pride it has inspired throughout Long Island's Puerto Rican and Dominican communities, spotlight Fire Island's fascinating history as an LGBTQ+ destination, and explore the many communities that make the barrier island one of Long Island's true crown jewels.Plus, we highlight National Foodie Day and some of the incredible restaurants that continue to make Long Island a premier culinary destination.Additional topics include the lasting impact of the U.S. Open at Shinnecock Hills and several standout public golf courses that keep Long Island's golf legacy thriving long after championship weekend.#ThisWeekendOnLongIslandFriday, June 26• Bop To The Top (18+) – The Paramount, Huntington• Summer Hours Begin – Adventureland• Beautiful: The Carole King Musical – Argyle Theatre (All Weekend)Saturday, June 27• Joe Avati – Patchogue Theatre for the Performing Arts• East End Farmers Markets – Greenport, Westhampton Beach & Sag Harbor• 4th Annual North Fork Pride Parade – Greenport Village• Bug Light Cruise – East End Seaport Museum• Fauna After Dark – Westhampton BeachSunday, June 28• Farmers Markets – Port Jefferson & SouthamptonFor more events and things happening across Long Island, visit discoverlongisland.com/events.#CelebriTEAThis week we're spotlighting Commack artist Ian James Roche, who has advanced to the quarterfinals of Johnny Depp's People's Artist Competition. Known for his large-scale pastel works, Roche is earning national recognition while representing Long Island's vibrant and growing arts community.Learn how to vote here: https://peoplesartist.org/vote/free/2...Connect with us:Instagram: @longislandteapodcastTikTok: @longislandteapodcastYouTube: Discover Long IslandFacebook: Long Island Tea PodcastX: @liteapodcastEmail: spillthetea@discoverlongisland.comShop: Discover Long Island Shop Hosted on Acast. See acast.com/privacy for more information.

Just going to pat myself on the back for the restraint shown in not including Joey in the episode art this week."The Making Of Mina The Hollower" Game Informer DocumentaryDiscussed: Sleepy BB, Sick Steve, Overworld, Summer Game Fest, post-leakage, direct predictions, Final Fantasy VII Revelation, revisiting Rebirth, Roche redemption, Resident Evil Veronica, the return of Claire, Guild Wars 3, Alien Isolation 2, Gen Atlas, Guild Wars 3, Tifa in Street Fighter, Vincent in Guilty Gear, Spyro: A Realm Beyond, Persona 6, Persona 4 Revival, Teddie's new voice, Mina the Hollower Find us everywhere: https://intothecast.onlineBuy some merch, if you'd like: https://shop.intothecast.onlineJoin the Patreon: https://www.patreon.com/intothecast---Follow Stephen Hilger: https://bsky.app/profile/stephenhilger.bsky.socialFollow Brendon Bigley: https://bsky.app/profile/bb.wavelengths.onlineProduced by AJ Fillari: https://bsky.app/profile/ajfillari.bsky.social---Season 8 cover art by Scout Wilkinson: https://scoutwilkinson.myportfolio.com/Theme song by Will LaPorte: https://ghostdown.online/---Timecodes:(00:00) - Intro (00:36) - Sleebby (01:57) - Catching up on all the announcements (02:14) - Overworld.vg and some SGF (06:24) - This episode is post-Nintendo Direct (07:02) - Nintendo Direct predictions (33:10) - Final Fantasy VII Revelation | SGF (47:25) - Resident Evil Veronica | SGF (48:58) - Alien Isolation 2 and Gen Atlas | SGF (49:30) - Guild Wars 3 | SGF (53:42) - Street Fighter 6 Year 4 | SGF (56:00) - Spyro: A Realm Beyond | SGF (57:05) - Persona 6 | SGF (01:03:15) - Persona 4 Revival | SGF (01:09:47) - Break (01:09:48) - Mina the Hollower | An update (01:34:30) - Warpping up ---Thanks to all of our amazing patrons, including our Eternal Gratitude members:Michael CBrian MSuperThisWayNick GStarfallrondoSusan H0nlygh0stsVincent JPatrick KEd ASamantha DNorth HeroSam HSnzznGregory Mark SCmndr BiscuiticemanChristian HRydan BCaleb HArden FEye of the DuckKaleNathan EJ. H. AjoelchronoMellowMatthew BRobin LPSeekingSeakingJimmerszoey!Vinny MMattKerry KBrian MNoah DZach DChristopher TDHugo WToddChris BLukerfuffleStephen YDaniel GEric FTaran WBrendan OChris ZClayton MZach RDylan NFederico VTigerz RevengeLogan HAlan RJohn AMike LmattjanzzDavid MHeavyPixelsKaleb HTyler JCorey ZSusan HBarry TRobert RChris JBrett Allen HDan SJack SGarrett CjimiiboJohn HDirch FJim EJim WTristan LEvan BAwfulHanzomin2Aaron GJean HTodd Nred_wagonNeilPeter BJohn VvErik MRedmage77Joshua JTony LDanny KGibson GKate Duncan BRichard MDaniel NSeth MJamesAndy HDemoEmmaLyn ECorey TCaleb WJake LJesse WMike TCodesMatt BWesleymebezacAlex LSergio LninjadeathdogRory BA42PoundMooseRobert MMichael WAndrewthis_JUSTINRyan O14.3 billion yearsBrendan KMegan BSecretAgentKoalaNoah OArcturusAndrew WhepaheChase ALoveDiesNick QChris MRBKaren HAdam FScott HAlexander SMatt HMurrayDavid PJason KMicah OKamrin HAndrew DKyle SPhilip N  ★ Support this podcast on Patreon ★

On September 13, 1991, 36-year-old Tom Roche dropped his longtime girlfriend off at work in Burbank, California. He told her he was heading home to work on his motorcycle, and the two made plans to meet for lunch later that day. But Tom never showed up.Editor: Shannon KeirceResearch/Writing: Haley GraySUBMIT A CASE HERE: Cases@DetectivePerspectivePod.com SOCIALInstagram: https://www.instagram.com/detperspective/Twitter: https://twitter.com/detperspectiveFIND DERRICK HERETwitter: https://twitter.com/DerrickLInstagram: https://www.instagram.com/DerrickLevasseurFacebook: https://www.facebook.com/DerrickVLevasseurCRIME WEEKLY AND COFFEECriminal Coffee Company: https://www.CriminalCoffeeCo.comCrime Weekly:  https://crimeweeklypodcast.com/shopADS:1. https://www.Rula.com/Detective - Get started on your mental health journey today!2. https://www.TryFUM.com - Use code DETECTIVE to get a FREE Gift with your Journey Pack!3. Pocket Hose - Text DETECTIVE to 64000 to get a FREE 360 Degree Rotating Pocket Pivot AND a Thumb Drive Nozzle with the purchase of ANY Pocket Hose Ballistic Hose!